openPR Logo
Press release

Pulmonary Arterial Hypertension Global Market 2022 Industry Analysis, Size, Share, Growth, Trends | Bayer AG, Gilead Sciences Inc., Johnson & Johnson, GlaxoSmithKline, Pfizer Inc.

The global pulmonary arterial hypertension market is expected to grow from $6.59 billion in 2021 to $7.04 billion in 2022 at a compound annual growth rate (CAGR) of 6.85%. The pulmonary arterial hypertension market is expected to reach $9.65 billion in 2026 at a CAGR of 8.22%.

The Business Research Company offers the Pulmonary Arterial Hypertension Global Market Report 2022 in its research report store. It is the most comprehensive report available on this market and will help gain a truly global perspective as it covers 60 geographies. The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by region and by country. It also compares the market's historic and forecast growth, and highlights important trends and strategies that players in the market can adopt.

Request FREE SAMPLE COPY of this research study:
https://www.thebusinessresearchcompany.com/sample.aspx?id=5954&type=smp

The pulmonary arterial hypertension market consists of sales of drugs by entities (organizations, sole proprietors, partnerships) that are used in the treatment of pulmonary arterial hypertension disease, which is a rare progressive disorder characterized by high blood pressure in the arteries of lungs. During this medical condition walls of the pulmonary arteries thicken and stiffen, making it difficult for the blood to flow through the lungs. The pulmonary arterial hypertension drugs relax the muscles in the wall of the blood vessels or increase the blood flow through the lungs or reverse the effect of the substance in the walls of blood vessels, which caused them to narrow.

Some key Pulmonary arterial hypertension market players are United Therapeutics Corporation, Bayer AG, Gilead Sciences Inc., Johnson & Johnson, GlaxoSmithKline, Pfizer Inc., Sandoz AG, Lupin Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Acceleron Pharma Inc., Eli Lilly and Company, Actelion Pharmaceuticals US Inc, Natco Pharma Ltd, Zydus Pharmaceutical USA, and Liquidia Technologies Inc.

The countries covered in the global Pulmonary arterial hypertension market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, Vietnam.

The regions covered in the global Pulmonary arterial hypertension' market is Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Pulmonary Arterial Hypertension Market Segmentation:
1) By Drug Class
Endothelin Receptor Antagonists (ERAs)
PDE-5 Inhibitors
Prostacyclin and Prostacyclin Analogs
SGC Stimulators

2) By Route of Administration
Oral
Intravenous/ subcutaneous
Inhalational

3) By Distribution channel
Retail
Online

See more on the report at https://www.thebusinessresearchcompany.com/report/pulmonary-arterial-hypertension-global-market-report

The Report's Table Of Contents includes
1. Executive Summary
2. Pulmonary Arterial Hypertension Market Characteristics
3. Pulmonary Arterial Hypertension Market Trends And Strategies
4. Impact Of COVID-19 On Pulmonary Arterial Hypertension
5. Pulmonary Arterial Hypertension Market Size And Growth
.....
26. Africa Pulmonary Arterial Hypertension Market
27. Pulmonary Arterial Hypertension Market Competitive Landscape And Company Profiles
28. Key Mergers And Acquisitions In The Pulmonary Arterial Hypertension Market
29. Pulmonary Arterial Hypertension Market Future Outlook and Potential Analysis
30. Appendix

This report covers the trends and market dynamics of the Pulmonary arterial hypertension market in major countries - Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The report also includes consumer surveys and various future opportunities for the market.

Directly purchase the report here: https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=5954

Contact Information:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info

Check out our blog: http://blog.tbrc.info/
And follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

About Us:
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that excels in company, market, and consumer research. It has published over 3000 industry reports, covering over 2500 market segments and 60 geographies. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. The reports are updated with a detailed analysis of the impact of COVID-19 on various markets.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Pulmonary Arterial Hypertension Global Market 2022 Industry Analysis, Size, Share, Growth, Trends | Bayer AG, Gilead Sciences Inc., Johnson & Johnson, GlaxoSmithKline, Pfizer Inc. here

News-ID: 2709337 • Views: 284

More Releases from The Business research company

Hepatitis Drugs Market Size, Share, Analysis, Growth, Trends, Industry Report 20 …
The global hepatitis drugs market is expected to grow from $17.12 billion in 2021 to $17.47 billion in 2022 at a compound annual growth rate (CAGR) of 2.07%. The global hepatitis drugs market is expected to grow to $21.68 billion in 2026 at a compound annual growth rate (CAGR) of 5.55%. The Business Research Company offers the Hepatitis Drugs Global Market Report 2022 in its research report store. It is the
Generator Sales Market Report 2022: Size, Share, Industry Demand, Growth Rate,To …
The global generator sales market is expected to grow from $21.66 billion in 2021 to $22.90 billion in 2022 at a compound annual growth rate (CAGR) of 5.73%. The global generator sales market is expected to grow to $28.62 billion in 2026 at a compound annual growth rate (CAGR) of 5.73%. The Business Research Company offers the Generator Sales Global Market Report 2022 in its research report store. It is the
Wood Coating Market In-Depth Industry Analysis, Strategies, Trends, Growth Rate …
The global wood coating market is expected to grow from $9.43 billion in 2021 to $10.02 billion in 2022 at a compound annual growth rate (CAGR) of 6.22%. The global wood coating market is expected to reach $12.77 billion in 2026 at a CAGR of 6.25%. The Business Research Company offers the Wood Coating Global Market Report 2022 in its research report store. It is the most comprehensive report available on
Marine Engines Market Share, Industry Size, Business Strategies, Growth Opportun …
The global marine engines market is expected to grow from $8.76 billion in 2021 to $9.38 billion in 2022 at a compound annual growth rate (CAGR) of 7.06%. The global marine engines market is expected to grow to $11.10 billion in 2026 at a compound annual growth rate (CAGR) of 4.32%. The Business Research Company offers the Marine Engines Global Market Report 2022 in its research report store. It is the

All 5 Releases


More Releases for Pulmonary

Global Pulmonary Arterial Hypertension Market Size
According to a new market research report published by Global Market Estimates, the Global Pulmonary Arterial Hypertension Market is projected to grow at a CAGR of 5.2% from 2022 to 2027. Congenital heart diseases and other ailments such as HIV infection, chronic liver disease (cirrhosis), and connective tissue disorders (scleroderma, lupus, and others) are fueling market expansion. Browse 153 Market Data Tables and 113 Figures spread through 185 Pages and in-depth TOC
New Study: Pulmonary Drugs Market Report
The pulmonary drugs market is expected to witness unprecedented growth in the near future, thanks to large number of approvals from the FDA. The FDA approved a large number of pulmonary drugs for major illnesses like small-cell lung cancer, tuberculosis, and pneumonia over the past few years. Additionally, newly approved drugs also treat newly found diseases like obstructive sleep apnea. These approvals are in line with the recent trend of
Pulmonary Drugs Market Forecast till 2025
Pulmonary Drugs Market – Boon for Diseased Lungs Pulmonary drugs can treat wide range of conditions, which are included within the ambit of pulmonary diseases such as pneumonia, allergic rhinitis, pulmonary hypertension, and others. . Pulmonary drugs provide medications for all types of pulmonary diseases, which is expected to fuel market growth in near future. The World Health Organization (WHO) states that most respiratory diseases are preventable and can be treated
Pulmonary Embolism - Pipeline Review, H2 2017
ReportsWorldwide has announced the addition of a new report title Pulmonary Embolism - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pulmonary Embolism - Pipeline Review, H2 2017, provides an overview of the Pulmonary Embolism (Cardiovascular) pipeline landscape. Pulmonary embolism is the sudden blockage of a major blood vessel (artery) in the lung, usually by a blood
Pulmonary Drugs 2024 Market Research Report
Global Pulmonary Drugs Market: Snapshot The global pulmonary drugs market has been the key area of focus and the most crucial market for the healthcare industry in the last couple of years. However, the market is expected to witness a significant decline over the forecast period with a -6.3% CAGR from 2016 to 2024. The market is anticipated to fall to US$28,082.1 mn from a valuation of US$48,039.7 mn in
03-15-2017 | Health & Medicine
TMR
Pulmonary Drug Delivery Devices Market: Demand for Pulmonary Drug Delivery Devic …
This report on pulmonary drug delivery devices studies the current as well as future prospects of the market globally. The stakeholders of this report include companies and intermediaries engaged in the manufacture and commercialization of various pulmonary/respiratory drugs and/or drug-device combinations as well as new entrants planning to enter this market. This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments